BeiGene, Ltd. has continued to make vast strides in the bio-tech industry. Institutional shareholders own a significant 45% of the company. BeiGene will change its NASDAQ ticker symbol to “ONC” and plans to rebrand as BeOne Medicines, part of their broad global oncology push. BeiGene has received favorable target prices from brokerages, with high anticipations surrounding TEVIMBRA, recently approved for Gastric and Gastroesophageal Junction Cancers. However, they also face a lawsuit from AbbVie over alleged theft of cancer therapy secrets. BeiGene has secured a global licensing agreement for MAT2A Inhibitor and is experiencing growth as witnessed in their Q3 report. They are continuously innovating, as observed with the appointment of new additions to key positions within the firm. Furthermore, the change in the NASDAQ ticker to 'ONC' has ignited substantial interest from investors. However, despite these advancements, institutional shareholders might consider drastic revisions following a 15% pullback that added to their one-year losses.
BeiGene, Ltd. News Analytics from Mon, 26 Feb 2024 08:00:00 GMT to Fri, 27 Dec 2024 12:27:54 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor -2
